Home / Business and Economy / Viatris Secures ¥40 Billion Loan for Growth
Viatris Secures ¥40 Billion Loan for Growth
6 Jul
Summary
- Viatris obtained a ¥40 billion senior unsecured term loan on July 1.
- The company reported positive Phase 3 results for Nefecon in IgA nephropathy.
- Viatris operates globally in four key segments within the healthcare sector.
Viatris Inc. recently bolstered its financial standing by entering into a ¥40 billion senior unsecured term loan agreement on July 1. This loan, provided by a group of lenders led by Mizuho Bank, will serve general business needs and refinance an existing debt of the same amount.
The healthcare company is also advancing its drug pipeline. On June 29, Viatris announced successful Phase 3 results for Nefecon in a Japanese trial for primary immunoglobulin A nephropathy. The drug, known as VR-205, demonstrated a significant reduction in urine protein levels over nine months.
Viatris operates globally, with its business divided into four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company's offerings include a range of prescription brand drugs, generics, complex generics, and biosimilars.
